Daratumumab + Lenalidomide, Bortezomib & Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN

Abstract

Daratumumab (DARA), a human CD38 mAb, is approved as monotherapy and in combination with standard-of-care (SoC) regimens for MM. In phase 3 studies, DARA-based regimens improved response rates, depth of response including stringent complete response (sCR) and minimal residual disease (MRD) negativity, and progression-free survival (PFS). In autologous stem cell transplant (ASCT)-eligible NDMM pts, RVd followed by high-dose therapy (HDT), ASCT, and consolidation is SoC in the US. GRIFFIN is a phase 2, randomized, active-controlled, US study of DARA plus RVd (D-RVd) in ASCT-eligible NDMM pts.